Cingulate Inc.
About Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$22.4M
- Total assets
- $15.1M
- Market cap
- $60.5M
- Operating margin
- 1464.8%
- Net margin
- 1649.4%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- -$1.4M
- Operating expenses
- $18.6M
- Operating income
- -$19.9M
- Net income
- -$22.4M
- EPS (basic)
- $-4.44
- EPS (diluted)
- $-4.44
Balance sheet
- Total assets
- $15.1M
- Current assets
- $12.0M
- Total liabilities
- $12.6M
- Current liabilities
- $10.3M
- Shareholders’ equity
- $2.5M
Cash flow
- Operating cash flow
- -$17.2M
- Investing cash flow
- -$162.1K
- Financing cash flow
- $16.1M
- Net cash flow
- -$1.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $60.5M
- EPS (diluted)
- $-4.44
- Shares outstanding
- 13.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 8, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.4M.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cingulate Inc..
Write a review
News about Cingulate Inc.
News & sentiment via Polygon.io
